BACKGROUND: AKR1B10 is considered to contribute to cell proliferation and chemoresistance. In the present study, we examined whether AKR1B10 expression is associated with disease-free survival in bladder cancer patients. METHODS: We obtained bladder cancer specimens from 10 patients before and after chemotherapy and measured AKR1B10 mRNA levels using real-time PCR. In addition, we conducted an immunohistochemical examination of AKR1B10 expression in 57 patients with bladder cancer before and after chemotherapy. RESULTS: AKR1B10 mRNA expression was significantly higher in the post-chemotherapy group than in the pre-chemotherapy group (p < 0.001). The average immunohistochemical intensity score in the pre-chemotherapy group was 0.83 ± 1.08, compared with the significantly higher score of 2.03 ± 1.03 in the post-chemotherapy group (p < 0.001). The disease-free survival rate of post-chemotherapy AKR1B10(+) patients (61.2%) was significantly lower than that of AKR1B10(-) patients (100%) (log-rank test, p = 0.039). CONCLUSIONS: Although the present study is small and preliminary, our data suggest that post-chemotherapy AKR1B10 expression may be associated with a poor prognosis in patients who received carboplatin-gemcitabine combination chemotherapy and underwent cystectomy. Further study is warranted to elucidate its clinical significance.
BACKGROUND:AKR1B10 is considered to contribute to cell proliferation and chemoresistance. In the present study, we examined whether AKR1B10 expression is associated with disease-free survival in bladder cancerpatients. METHODS: We obtained bladder cancer specimens from 10 patients before and after chemotherapy and measured AKR1B10 mRNA levels using real-time PCR. In addition, we conducted an immunohistochemical examination of AKR1B10 expression in 57 patients with bladder cancer before and after chemotherapy. RESULTS:AKR1B10 mRNA expression was significantly higher in the post-chemotherapy group than in the pre-chemotherapy group (p < 0.001). The average immunohistochemical intensity score in the pre-chemotherapy group was 0.83 ± 1.08, compared with the significantly higher score of 2.03 ± 1.03 in the post-chemotherapy group (p < 0.001). The disease-free survival rate of post-chemotherapy AKR1B10(+) patients (61.2%) was significantly lower than that of AKR1B10(-) patients (100%) (log-rank test, p = 0.039). CONCLUSIONS: Although the present study is small and preliminary, our data suggest that post-chemotherapy AKR1B10 expression may be associated with a poor prognosis in patients who received carboplatin-gemcitabine combination chemotherapy and underwent cystectomy. Further study is warranted to elucidate its clinical significance.
Authors: Dalsu Baris; Margaret R Karagas; Castine Verrill; Alison Johnson; Angeline S Andrew; Carmen J Marsit; Molly Schwenn; Joanne S Colt; Sai Cherala; Claudine Samanic; Richard Waddell; Kenneth P Cantor; Alan Schned; Nathaniel Rothman; Jay Lubin; Joseph F Fraumeni; Robert N Hoover; Karl T Kelsey; Debra T Silverman Journal: J Natl Cancer Inst Date: 2009-11-16 Impact factor: 13.506
Authors: Stephan Langer; Maria Kokozidou; Christian Heiss; Jennifer Kranz; Tina Kessler; Niklas Paulus; Thilo Krüger; Michael J Jacobs; Christina Lente; Thomas A Koeppel Journal: Kidney Int Date: 2010-09-29 Impact factor: 10.612
Authors: H Yoshitake; M Takahashi; H Ishikawa; M Nojima; H Iwanari; A Watanabe; H Aburatani; K Yoshida; K Ishi; K Takamori; H Ogawa; T Hamakubo; T Kodama; Y Araki Journal: Int J Gynecol Cancer Date: 2007-04-09 Impact factor: 3.437
Authors: Stefan Heringlake; Michael Hofdmann; Anette Fiebeler; Michael P Manns; Wolff Schmiegel; Andrea Tannapfel Journal: J Hepatol Date: 2009-11-25 Impact factor: 25.083